Advertisement

Topics

Selumetinib Fails to Improve Outcomes in KRAS-Mutant NSCLC

23:27 EDT 19 Oct 2016 | Cancer Networks

The addition of selumetinib to docetaxel failed to improve progression-free and overall survival in patients with KRAS-mutated locally advanced or metastatic NSCLC.

Original Article: Selumetinib Fails to Improve Outcomes in KRAS-Mutant NSCLC

NEXT ARTICLE

More From BioPortfolio on "Selumetinib Fails to Improve Outcomes in KRAS-Mutant NSCLC"

Quick Search
Advertisement
 

Relevant Topic

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...